Accretive Health (AH)
AH (NYSE)
$11.08
+0.21
+1.93%
Today's Range: 10.90 - 11.18 |
AH Avg Daily Volume: 0
| Last Update: 05/17/13 - 4:01 PM EDT |
| Volume: 260,786 |
| YTD Performance: -4.32%
|
| Open: $10.90 |
| Previous Close: $10.87 |
| 52 Week Range: $8.55 -
$14.19 |
| Oustanding Shares: 0 |
| Market Cap: 0 |
6-Month Chart
TheStreet Ratings Grade for AH
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
|
|
|
|
| Moderate Buy |
|
|
|
|
| Hold |
|
|
|
|
| Moderate Sell |
|
|
|
|
| Strong Sell |
|
|
|
|
| Mean Rec. |
0.00 |
0.00 |
0.00 |
0.00 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
63.94 |
|
| Price Earnings Comparisons: |
| AH |
Sector Avg. |
S&P 500 |
| 63.94 |
0.00 |
0.00 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
-14.90%
|
-6.58%
|
-87.41%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
0.00 |
0.00 |
0.00 |
| Net Income |
0.00 |
0.00 |
0.00 |
| EPS |
0.00 |
0.00 |
0.00 |
| Earnings for AH: |
| EBITDA |
0.00B |
| Revenue |
0.00B |
|
Average Earnings Estimates
;Qtr (06/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (03/12);Qtr (06/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$0.05 |
$0.07 |
$0.28 |
$0.35 |
| Number of Analysts |
3 |
3 |
4 |
1 |
| High Estimate |
$0.06 |
$0.08 |
$0.33 |
$0.35 |
| Low Estimate |
$0.04 |
$0.05 |
$0.22 |
$0.35 |
| Prior Year |
$0.01 |
$-0.01 |
$n.a. |
$0.28 |
| Growth Rate (Year over Year) |
433.33% |
766.67% |
n.a.% |
25.00% |
Nov 08, 2012 | 8:25 AM EST
Shares of AH now seen reaching $15, Oppenheimer said. Estimates also lowered on 3Q results. Outperform rating.
Aug 09, 2012 | 7:38 AM EDT
Shares of AH now seen reaching $11, according to Credit Suisse. Estimates also reduced, given higher legal costs. Outperform rating.&nb...
May 01, 2012 | 7:36 AM EDT
AH was downgraded to Neutral from Hold, UBS said. $11 price target. Possibly more issues lurking around the corner.
Apr 03, 2012 | 8:17 AM EDT
AH was downgraded from Buy to Neutral, Goldman Sachs said. $24 price target. Fairview contract loss could hang over the stock.
Mar 30, 2012 | 6:27 AM EDT
AH was downgraded from Outperform to Neutral, Robert Baird said. $21 price target. Company just lost a major contract.
| Dec 30, 2011 | 12:30 PM EST
These leaders have shown strong price action recently and hold promise for rising profitability.
| Nov 30, 2011 | 8:30 AM EST
News that China cut the reserve requirements for banks has been welcomed by the global markets.
Nov 30, 2011 | 8:05 AM EST
AH was upgraded from Perform to Outperform, Oppenheimer said. $31 price target. Well positioned to meet or exceed revenue expectations ...
| Nov 04, 2011 | 2:45 PM EDT
These stocks have been making big moves -- up and down -- despite the market whipsaws caused by Europe.
